{"id":"simvastatin-plus-ticagrelor","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Muscle pain or myopathy"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dyspnea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Simvastatin is an HMG-CoA reductase inhibitor that decreases LDL cholesterol and reduces atherosclerotic plaque formation. Ticagrelor is a P2Y12 receptor antagonist that prevents platelet activation and thrombosis. Together, they address both lipid management and thrombotic risk in cardiovascular disease.","oneSentence":"Simvastatin reduces cholesterol synthesis while ticagrelor inhibits platelet aggregation, combining lipid-lowering and antiplatelet effects for cardiovascular protection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:09.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with elevated cholesterol"},{"name":"Secondary prevention of cardiovascular events in high-risk patients"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02428374","phase":"PHASE4","title":"Role of Immune Responses After Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2015-05","conditions":"Myocardial Fibrosis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zocor & Brilinta"],"phase":"marketed","status":"active","brandName":"Simvastatin plus ticagrelor","genericName":"Simvastatin plus ticagrelor","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Simvastatin reduces cholesterol synthesis while ticagrelor inhibits platelet aggregation, combining lipid-lowering and antiplatelet effects for cardiovascular protection. Used for Acute coronary syndrome with elevated cholesterol, Secondary prevention of cardiovascular events in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}